Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS:
ANP and LANP decreased the activation of ERK 1/2 over a concentration range of 0.01 microM to 10 microM. ANP and LANP's maximal inhibition of the phosphorylation of ERK 1/2 kinase were 94% and 88% (p < 0.0001), respectively. ANP had significant effects within five min at its 10 microM concentration. The inhibition of ERK 1/2 lasted for at least two h, where it was maximal, secondary to both peptides. Their ability to inhibit ERK 1/2 was inhibited by cyclic GMP antibody and cyclic GMP itself inhibited ERK 1/2 phosphorylation. CONCLUSION:
ANP and LANP both inhibit ERK 1/2 kinase mediated via cyclic GMP as part of their anticancer mechanism(s) of action.
|
Authors | Ying Sun, Ehrentraud J Eichelbaum, Hai Wang, David L Vesely |
Journal | Anticancer research
(Anticancer Res)
2006 Nov-Dec
Vol. 26
Issue 6B
Pg. 4143-8
ISSN: 0250-7005 [Print] Greece |
PMID | 17201125
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Enzyme Inhibitors
- Atrial Natriuretic Factor
- Mitogen-Activated Protein Kinase 1
- Mitogen-Activated Protein Kinase 3
- Cyclic GMP
|
Topics |
- Atrial Natriuretic Factor
(pharmacology)
- Cell Line, Tumor
- Cyclic GMP
(immunology)
- Dose-Response Relationship, Drug
- Enzyme Inhibitors
(pharmacology)
- Humans
- Male
- Mitogen-Activated Protein Kinase 1
(antagonists & inhibitors)
- Mitogen-Activated Protein Kinase 3
(antagonists & inhibitors)
- Prostatic Neoplasms
(enzymology, pathology)
|